MedPacto Inc. (235980)

Overview

MedPacto, Inc. is a pioneering drug discovery and development firm based in Seoul, South Korea, with a focused commitment to creating innovative therapeutics for cancer and autoimmune diseases. Through its dedication to research and development, MedPacto aims to deliver next-generation treatments that target the complex mechanisms of these conditions. With a strategic focus on biopharmaceutical innovation, the company seeks to address the unmet medical needs of patients worldwide, leveraging South Korea's growing prominence in the global healthcare research arena.

Products and Services

• ME-1601mAb

  This investigational product by MedPacto targets BSP1, a novel cancer target, indicating its use in treating various forms of cancer. The development of ME-1601mAb reflects the company's focus on identifying and targeting specific biological pathways involved in cancer progression.

• MS-1601A

  MS-1601A is another innovative therapeutic candidate from MedPacto, designed to target TRG1 for the treatment of both cancers and autoimmune diseases. This dual approach highlights the company's capability in addressing complex diseases with overlapping biological mechanisms through targeted therapy.

• Vactosertib

  Targeting solid tumors, vactosertib is MedPacto's response to the urgent need for more effective treatments against solid forms of cancer. It showcases the company's commitment to extending the boundaries of cancer therapy and improving survival rates and quality of life for patients suffering from these debilitating conditions.